Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 7/20 | 0.47 |
| ▸ | ESR1 | P03372 | 5/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PDE1A | P54750 | 1/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6103493 | 0.91 | PDE5A (0.39) | PDE5AMEN1HPGDKMT2AALDH1A1 | |
| SCHEMBL5413892 | 0.87 | PDE5A (0.46) | PDE5AMEN1HPGDKMT2AALDH1A1 | |
| SCHEMBL5355834 | 0.86 | TDP2 (0.40) | PDE5AKMT2AMTORHDAC1HDAC2 | |
| SCHEMBL5375808 | 0.85 | MTOR (0.39) | PDE5AKMT2AMTORHDAC1HDAC2 | |
| SCHEMBL5410928 | 0.81 | PDE5A (0.51) | PDE5AMEN1HPGDKMT2AALDH1A1 | |
| SCHEMBL5369656 | 0.80 | PDE5A (0.38) | PDE5AMEN1HPGDKMT2AALDH1A1 | |
| SCHEMBL5335286 | 0.79 | PDE5A (0.44) | PDE5AMEN1HPGDKMT2AALDH1A1 | |
| SCHEMBL5371349 | 0.78 | MTOR (0.40) | PDE5AMEN1HPGDKMT2AALDH1A1 | |
| SCHEMBL5377740 | 0.75 | PDE5A (0.41) | PDE5AMEN1HPGDKMT2AALDH1A1 | |
| SCHEMBL5359600 | 0.73 | PDE5A (0.43) | PDE5AMEN1KMT2AHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814885-A2 | NOVEL BICYCLIC HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2006073610-A2 | NOVEL BICYCLIC HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | WO | claimed |
| US-20060128729-A1 | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-06-15 | — | — | US | claimed |
| EP-1814885-A2 | NOVEL BICYCLIC HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | disclosed |
| WO-2006073610-A2 | NOVEL BICYCLIC HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20060128729-A1 | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | PTPN5, PTPN1, PTPN7 | PDE5A 195/4885ESR1 3077/4885ESR2 2906/4885 |
| US-20060128729-A1 | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | HPSE, ENGASE, UGCG | PDE5A 3544/4885ESR1 3487/4885ESR2 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.